Treatment preference for weekly DPP-4 inhibitors versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus

INTERVENTION: Intervention name : Trelagliptin 100 mg, Alogliptin 25 mg Dosage And administration of the intervention : Trelagliptin preceding group (T‐A group): 100 mg of trelagliptin tablets, orally, once a week for 8 weeks, followed by 25 mg of alogliptin, orally, once a day for 8 weeks. Control intervention name : Alogliptin 25 mg, Trelagliptin 100 mg Dosage And administration of the control intervention : Alogliptin preceding group (A‐T group): 25 mg of alogliptin, orally, once a day for 8 weeks, followed by 100 mg of trelagliptin, orally, once a week for 8 weeks. CONDITION: Type 2 diabetes mellitus PRIMARY OUTCOME: Patient Preference for Treatment Interviewed from Participants Using Standardized Questions at the End of Treatment Period SECONDARY OUTCOME: Patient Preference for Treatment Interviewed from Participants Using Standardized Questions at the End of Treatment Period in Selected Participants by Drug and Background Factors INCLUSION CRITERIA: 1. Participants who have been diagnosed with type 2 diabetes mellitus 2. Participants who are being treated with any of the following DPP‐4 inhibitors for at least 8 weeks prior to the start of treatment period (Week 0). ‐ Sitagliptin : 50 mg once daily ‐ Alogliptin : 25 mg once daily ‐ Linagliptin : 5 mg once daily ‐ Teneligliptin : 20 mg once daily ‐ Saxagliptin : 5 mg once daily 3. Participants who were judged by the investigators possible to change the treatment from once‐daily dosing of DPP‐4 inhibitor shown in Inclusion Criteria 2 to study drug trelagliptin 100 mg or alogliptin 25 mg 4. Participants whose HbA1c value measured within 8 weeks prior to the start of treatment period (Week 0) is below 10.0% 5. Participants who responded to DTSQ (Diabetes Treatment Satisfaction Questionnaire) at the start of treatment period (Week 0) 6. Participants who were judged by the investigators capable to understand the contents of this clinical